Trillium Therapeutics (TRIL) versus Its Rivals Head-To-Head Review
Trillium Therapeutics (NASDAQ: TRIL) is one of 94 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Trillium Therapeutics to related businesses based on the strength of its dividends, institutional ownership, valuation, profitability, risk, earnings and analyst recommendations.
This is a summary of current ratings and price targets for Trillium Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trillium Therapeutics Competitors||164||551||1212||16||2.56|
Trillium Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 223.53%. As a group, “Biotechnology” companies have a potential upside of 54.02%. Given Trillium Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than its peers.
Risk & Volatility
Trillium Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Trillium Therapeutics’ peers have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
This table compares Trillium Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trillium Therapeutics Competitors||-889.02%||-184.03%||-26.48%|
Insider & Institutional Ownership
48.0% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 18.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Trillium Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||-$28.62 million||-1.37|
|Trillium Therapeutics Competitors||$224.58 million||$58.12 million||-1.01|
Trillium Therapeutics’ peers have higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Trillium Therapeutics beats its peers on 7 of the 12 factors compared.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.